Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials

BACKGROUND: Participant retention is a key factor that affects clinical trial integrity. Trial protocols estimate attrition as a function of sample size calculations. Alzheimer’s disease (AD) is an area of active treatment development. We aimed to quantify the association between trial duration and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ritchie, Marina, Gillen, Daniel L., Grill, Joshua D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662394/
https://www.ncbi.nlm.nih.gov/pubmed/37990339
http://dx.doi.org/10.1186/s13195-023-01352-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662394/
https://www.ncbi.nlm.nih.gov/pubmed/37990339
http://dx.doi.org/10.1186/s13195-023-01352-0

Ejemplares similares